Overview

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Phase:

Phase 2

Details

Lead Sponsor:

Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.

Collaborator:

Eisai Inc.

Treatments:

Azacitidine
Decitabine
Imatinib Mesylate